Science raises $400M as US venture megadeals defy public tech market slump
Despite a sharp downturn in public tech equities, US startups secured eight nine-figure funding rounds, led by brain-computer interface maker Science raising $400 million.
Venture capitalVenture capitalMoney invested in young companies in return for a share of them. Open in glossary investors continued to write massive checks for private technology companies, even as public tech stocks suffered a steep selloff over recent days. A persistent drop in public equities could eventually squeeze private market valuations, but recent deal activity shows major funding rounds are still closing across sectors like neurotech, artificial intelligence, and biotech.
Neurotech and AI secure major rounds
Alameda-based brain-computer interfaceBrain-computer interfaceA direct communication link between an electrical device and the human brain. Open in glossary company Science led domestic funding by securing $400 million in a Series DSeries DA fourth major round of venture capital funding for a mature private startup looking to scale. Open in glossary round. The investment pushes the neural engineering startup’s total capital raised to more than $900 million.
Artificial intelligence startups also captured substantial capital. Model ML, an AI platform designed for professional and financial services, closed a $250 million Series BSeries BA company's second major round of venture capital funding after seed financing. Open in glossary round at a $1.5 billion valuationValuationWhat a company is judged to be worth. Open in glossary. The round was led by General Atlantic and QED Investors. Palo Alto-based Noeri also launched with $110 million in initial capital led by Menlo Ventures to build self-improving enterprise AI models.
Biotech and deep tech rounds exceed $100M
Biotechnology startups accounted for multiple eight- and nine-figure transactions. Galvanize Therapeutics picked up $130 million in Series D capital to advance pulsed electric field ablation treatments. Watertown-based Marrow Therapeutics launched with $173 million across two rounds, including a $120 million Series B to treat blood disorders. In San Diego, Seawolf Therapeutics exited stealth with $100 million for its DNA delivery platform.
Hardware, deep techDeep techStartups founded on difficult, breakthrough scientific research rather than standard software. Open in glossary, and resource technologies also saw significant interest:
- General Flash raised $128 million across seed and Series A rounds to build new production methods for critical metals.
- Ramon.Space raised $124 million in Series B financing to develop space-based computing infrastructure.
- BrightAI collected $97 million to deploy sensors, drones, and robotics across heavy utility and energy infrastructure.
- Vincue pulled in $93 million in growth capital for its vehicle intelligence system.
Outside the United States, London-based AI drug discovery company Isomorphic Labs secured the largest deal of the week, closing a $5 billion Series C financing round led by Greenoaks and Sequoia Capital.
How does this story land?
One tap per reader.
Quick poll
Will public market tech drops slow private venture megadeals next quarter?
One tap. No sign-up.
Ask this story
Still have a question?
Answers use only what is in this story. They are written by AI and can be wrong.